The ε4 haplotype of APOE is the only undisputed genetic risk factor for late onset Alzheimer's disease (LOAD). It has been proposed that at least two other polymorphisms in the promoter of the APOE gene (-219G>T, and -491A>T) might also contribute to disease susceptibility, and modulate the impact of structural changes in the ApoE protein, by altering its expression. In order to assess the extent of cis-acting influences on APOE expression in human brain, highly quantitative measures of allele discrimination were applied to cortical RNA from individuals heterozygous for the epsilon  alleles. A small, but significant, increase in expression of the ε4 allele was observed relative to that of the ε3 and ε2 alleles (P < 0.0001). Similar differences were observed in brain tissue from confirmed LOAD subjects, and between cortical regions BA10 (fronto-polar) and BA20 (inferior temporal). Stratification of ε4/ ε3 allelic expression ratios according to heterozygosity for the -219G>T promoter polymorphism revealed significantly lower relative expression of haplotypes containing the -219T allele (P = 0.02). Our data indicate that, in human brain, most of the cis-acting variance in APOE expression is accounted for by the ε4 haplotype, but there are additional, small, cisacting influences associated with promoter genotype.
Introduction
Apolipoprotein E (ApoE) serves a central role in lipid metabolism and is the major apolipoprotein synthesized in brain (1) . The ApoE protein exists as three common isoforms (designated ApoE2, ApoE3 and ApoE4), resulting from two non-synonymous single nucleotide polymorphisms in the APOE gene. These isoforms differentially impact on a variety of biological parameters, including plasma cholesterol levels (2), neurite outgrowth (3) and amyloid deposition (4) .
Possession of the ε4 allele of the APOE gene (encoding ApoE4) is the only undisputed genetic risk factor for the common, late-onset, form of Alzheimer's disease (LOAD), increasing risk in a dose-dependent manner (5, 6) . However, the ε4 allele is neither necessary nor sufficient for expression of the disease, and a large proportion of ε4 homozygotes surviving to 80 years do not show cognitive impairment (7) . The ε2 allele (encoding ApoE2) confers a protective effect (8) .
It has been postulated that, in addition to the structural changes in ApoE, cis-acting variation within APOE regulatory sequence might also contribute to disease susceptibility, by influencing gene expression. Transgenic mouse models indicate that APOE dosage can significantly influence pathological hallmarks of human Alzheimer's disease, including amyloid deposition and neuritic degeneration (9, 10) . Furthermore, that cis-acting regulatory variants in human APOE have the potential to influence LOAD susceptibilty is suggested by a study in which variation in quantitative measures of peripheral lipid metabolism were better explained by considering genotype data from additional polymorphic sites in the vicinity of APOE, rather than ε2-4 status alone (11) . It should, however, be noted that the implications of that study for Alzheimer's disease are unknown, as it is unclear if those aspects of APOE function as indexed by peripheral lipid metabolism are relevant to LOAD pathogenesis.
at Pennsylvania State University on February 23, 2013 http://hmg.oxfordjournals.org/ Downloaded from 6 Expression ratios derived from the 11 ε3ε4 heterozygotes from the LOAD sample yielded a similar pattern, with an average 15% relative increase in ε4 compared with ε3 expression (P < 0.0001). There was again good reproducibility of individual cDNA ratios across assays (SD/mean = 0.04), with averaged increases ranging from between 9% and 19% (fig 1) . No significant differences were observed between ratios derived from the initial sample and those from LOAD cases (P = 0.76).
Ratios obtained for the additional 13 ε3ε4 heterozygotes for which tissue from both BA10 and BA20 were available again showed a significant increase in expression of the ε4 allele (BA10 mean increase = 11%, P < 0.0001, BA20 mean increase = 10%, P < 0.0001). Withinsubject comparisons between the two brain regions indicated no significant differences in the extent of allelic imbalance (paired t test, P = 0.28).
A smaller difference was observed in the relative expression of ε2 and ε3 alleles (SNP 472C>T) in the initial sample of 11 ε2ε3 heterozygotes (fig 2) . The average increase in the 472C (ε3) allele over the 472T (ε2) allele across experiments was only 4% (ratio = 1.04), ranging from equal expression (ratio = 1) to a 10% relative increase in the ε3 allele (ratio = 1.10). Although this just meets conventional criteria for significance (P = 0.04), an increase in relative ε3 expression was not observed in the 4 ε2ε3 heterozygotes from the USA sample, in tissue derived from either BA10 or BA20 (mean ratios = 1.00 and 0.99, respectively).
Combining data from all 15 samples of frontal cortex yielded a mean ε3 /ε2 ratio of 1.03 (P = 0.06).
Two of the initial 60 samples were ε2ε4 heterozygotes, and therefore heterozygous at both SNPs 334T>C and 472C>T. This allowed comparison between allele ratios derived from the two separate assays, which, in the absence of alternative splicing, should be comparable, 7 despite being amplified and assayed using different primer sets. The cDNA ratios, corrected by the average genomic for each assay, were 1.14 and 1.10 for one sample, and 1.12 and 1.08 for the other sample, at SNPs 334T>C and 472C>T, respectively. Thus, in both cases, calculated ratios differed by only 4% between the two independent assays. This sample is too small for statistical analysis, but, as expected from our observations that the relative expression of ε4 > ε3, while ε3 ≥ ε2, the ε4 allele  was expressed at a higher level than ε2 in each case.
In order to investigate the influence of known promoter polymorphisms on allelic expression, the 60 unrelated Caucasians and the 22 Caucasian LOAD cases were genotyped for promoter SNPs -491A>T and -219G>T (for observed allele frequencies, see table 1). Although other variants of potential regulatory significance exist (e.g. -427T>C, +113G>C), these particular polymorphisms were selected on the basis of having the strongest prior evidence for association with LOAD (16) . The sample used for within-subject comparisons between brain region were not included in this analysis as it is ethnically more heterogenous. The use of samples with different genetic backgrounds is potentially problematic for calculating the conditional diplotype probabilities as the diplotypes are less likely to follow Hardy-Weinberg expectations.
In order to determine if any of the variance in relative ε4 expression is attributable to heterozygosity at the promoter sites, the corrected cDNA ratios obtained from analysis of ε3ε4 heterozygotes at SNP334T>C were stratified according to whether individuals were heterozygous or homozygous for the two promoter loci.
Ratios derived from the 13 -219G>T heterozygotes and 13 -219G>T homozygotes were compared by use of a two-factorial ANOVA, where LOAD diagnosis was included as a factor. Of the 13 -219G>T homozygotes, 9 were homozygous for the -219T allele and 4 were at Pennsylvania State University on February 23, 2013 http://hmg.oxfordjournals.org/ Downloaded from homozygous for the -219G allele. The average increase of the ε4 allele, relative to ε3, was 12% in -219G>T heterozygotes, range = 6 -23%, compared with 16% in -219G>T homozygotes, range 9 -25% (fig 3) . A significant main effect of heterozygosity versus homozygosity at the -219G>T polymorphism was observed (P = 0.02), with no significant effect of LOAD diagnosis (P = 0.43). Knowledge of phase is required to allow inference about the direction of effect of the 219G and T alleles. Diplotypes are unambiguous with respect to individuals who are homozygous at the promoter polymorphism, but not for those who are heterozygous at both this and the assayed site. However, given the observed haplotype frequencies, the probability is 0.85 that, for -219G>T / 334T>C double heterozygotes, the 219G nucleotide is in phase with 334T (ε3) and the 219T nucleotide is in phase with 334C (ε4). Since the -219G>T heterozygotes showed a reduced relative increase in ε4 expression compared with -219G>T homozygotes, and since in the case of the heterozygotes, the -219T allele is predicted to be in phase with the ε4 allele in 85% of cases, we can infer that the -219T allele is associated with reduced APOE expression compared to the -219G allele.
Of the 26 ε3ε4 heterozygotes included in the analysis, 6 were heterozygous for the -491A>T polymorphism, one was homozygous for the -491T allele and 19 were homozygous for the -491A allele. The average increase of the ε4 allele, relative to ε3, was 16% in -491A>T heterozygotes, range = 9 -25%, compared with 14% in -491A>T homozygotes, range = 6 -23% ( fig 4) . Differences in allele ratio did not approach statistical significance (P = 0.57).
Again, there was no significant effect of LOAD diagnosis (P = 0.73). However, given individual genotypes at SNPs 334T>C and -219G>T, for 4 of the 6 -491A>T heterozygotes, the probability is only 0.61 that the -491T nucleotide is in phase with the 334T (ε3) allele, and the -491A nucleotide is in phase with the 334C (ε4) allele. As the phase probability is not much greater than chance, it is likely that phase will be reversed in a proportion of cases, distorting any directional effect on ε4 expression. The -491A>T heterozygote with the greatest phase certainty (probability = 0.99) was predicted to possess the -491A nucleotide in phase with -219G and 334C (ε4), and the -491T nucleotide in phase with -219G and 334T (ε3). This sample, the only individual that was homozygous for the 'high expression' 219G allele whilst heterozygous for the -491A>T polymorphism, showed the greatest elevation in relative 334C (ε4) expression of all assayed samples (25%).
Discussion
Using a highly quantitative method of allele discrimination (18, 19) , we have compared the relative expression of the APOE ε2, ε3 and ε4 alleles in brain RNA from individual heterozygotes. By comparing the relative expression of alleles within individuals, the assay has a perfect internal control for variables such as RNA quality, disease status (with the exception of multiplicative effects between other risk factors and gene expression), cell loss as a result of degenerative changes, and the trans-acting effects of other loci or environmental factors (e.g. cause of death, drug treatment, nutritional status etc). All of these variables can be expected to influence each allelic variant of mRNA equally. The assay therefore permits detection of small cis-acting influences on gene expression, even with a background of large inter-individual variation in total gene expression, a feature that has been previously observed in studies of total APOE mRNA expression (e.g. 20). A further advantage is that the assay is robust to secondary effects on gene expression. For example, possession of an allele that influences disease as a result of impaired protein function might, by trans-acting homeostatic mechanisms, result in a compensatory increase in gene expression.
We found increased expression of the ε4 allele over that of the ε3 allele in ε3ε4
heterozygotes, a finding that replicated in two additional samples, one of LOAD subjects, the other a mixed population of subjects with neuropsychiatric disorders. We also observed a small increase in relative ε3 expression in ε2ε3 individuals, but this finding did not replicate in the small number of neuropsychiatric patients in which this genotype was observed.
Although not a comprehensive survey of different brain regions, analysis of the frontal and temporal cortex yielded no evidence for differences by neuroanatomical region.
The relatively small difference in allele ratio observed in ε3ε4 heterozygotes in this study is in stark contrast with the findings of a previous study (12) , where an RFLP-based design was used. In that study, a large increase was observed in the level of ε3 relative to ε4 mRNA in both control and LOAD samples, although smaller differences were seen in the LOAD group.
Our data are more compatible with those of a subsequent study (13) , in which no major differences in the expression of the two alleles were found in either control or LOAD ε3ε4
heterozygotes. It is also notable that, in the subsequent study (13) , an average 4% relative increase in ε4 expression was found, with a maximum of 22%. Using a similar RFLP-based design to the previous study, they also showed that estimation of allele ratio using this method is critically dependent on the number of PCR cycles (due to digestion-resistant heteroduplex formation), suggesting that the former results were due to artefact. The primer extension method used in the present study is unaffected by this problem and thus the present data are likely to provide a more accurate estimate of relative allelic expression of brain APOE.
The small increase in ε4 expression observed in this study could possibly reflect an intrinsic effect of the alleles on transcription efficiency or RNA stability. Alternatively, the finding differences for ε3ε4 heterozygotes, since inter-individual differences in ratios were largely preserved between separate RT reactions.
Our finding of increased expression of the ε4 allele at the RNA level is consistent with a recent study in which the encoded ApoE4 isoform was found to account for an elevated proportion of total ApoE protein in the CSF of ε3ε4 heterozygotes (21) . This finding is in contrast to measures of ApoE4 in plasma (2, 21) , where it is associated with lower protein expression, suggesting important allele-specific differences in the CNS and periphery in the control of synthesis and/or degradation of ApoE.
The magnitude of ε4 over-expression was found to be virtually identical between the initial sample and the sample of confirmed LOAD cases. The initial sample was not selected to be a specific control group for the LOAD sample, and although it did not contain any individuals with a diagnosis of AD, it is possible that some individuals might have developed the disease had they survived to old age. However, that no differences were observed between this sample and confirmed LOAD cases is consistent with previous comparisons using agematched control groups in terms of both relative ε4 RNA expression (13) and the relative level of ApoE4 protein (21) , suggesting that, if there are common risk factors for LOAD that influence risk of disease by altering APOE expression, they do not selectively interact to markedly increase the expression of specific APOE mRNA species. While significant, the influence of cis-acting polymorphisms on steady state levels of APOE mRNA in cerebral cortex is small, with a maximum relative difference in expression observed in this study of 25%. The 56 APOE heterozygotes assayed in this study provided >99% power to detect the effect of a distinct regulatory variant occurring in the general population at a frequency of 0.05, and almost 90% power to detect the effect of one present at a frequency of polymorphisms in and around APOE exerting large direct effects on net APOE mRNA expression.
The third objective of this study was to determine if APOE mRNA levels in vivo are influenced by polymorphisms that affect transcription activity in vitro, and which have, in several studies, been associated with LOAD. Stratification of observed ε4 / ε3 allele ratios according to heterozygosity for the promoter polymorphisms indicated a very small but statistically significant effect of the -219G>T polymorphism on allelic expression, consistent with it having a functional effect in brain. The -219T allele has previously been associated with reduced transcriptional activity in vitro (17) and with reduced plasma ApoE in vivo (22) .
The present finding of a reduced ratio of ε4 / ε3 expression when the probability is that the ε4 allele is in phase with the -219T allele, and the ε3 allele in phase with the -219G allele, suggests that the -219T allele also decreases APOE expression in brain. As with measures of total expression, our data do not allow us to distinguish between direct and indirect association, but the consistency of our finding with in vitro studies suggests that this is a direct effect.
The conditional probabilities for diplotypes suggest that, for approximately 15% of -219G>T heterozygotes (i.e. 2 of the 13), the higher expression -219G allele is in phase with ε4 in ε3ε4 individuals. As we do not know which, if any, individual diplotypes in this analysis are misclassified, we cannot accurately assess the impact of this on our estimate of the magnitude of effect. However, if we assume that the two heterozygotes displaying the least reduction in ε4 / ε3 ratio are misclassified, we obtain an estimate of the maximum possible size of the effect. Excluding these from analysis reveals a mean net effect of the 219T allele of a 6 % reduction in relative ε4 expression. We stress that this analysis provides a guide to the maximum effect; we cannot conclude that the effect is of this size since we have no compelling case to exclude any single individual from the analysis. genomic DNA was extracted using standard phenol-chloroform procedures, and total RNA extracted using the RNAwiz™ isolation reagent (Ambion). Total RNA was treated with DNAse prior to reverse transcription using random decamers and the RETROscript™ kit (Ambion).
Genotyping
Genotyping for APOE ε2 / ε3/ ε4 was performed using an RFLP-based assay described previously (25) . Genotyping of SNP -491A>T was performed using SNaPshot primer extension, with amplification primers 5'-GCCTAGCCCCACTTTCTTTT-3' and 5'-CACAGTGGGCGAATCACTTA-3', and the extension primer 5'-CGAATCACTTAAGGTCAGGAG-3'. SNP -219G>T was genotyped using primers 5'-AGAATGGAGGAGGGTGTCCG-3' and 5'ACTCAAGGATCCCAGACTTG-3', followed by restriction digestion with HpaII and EcoN1.
Allele Expression Assay
Genomic DNA from all subjects was initially genotyped, as described, in order to identify heterozygotes for SNPs 334T>C (ε4 heterozygotes) and 472C>T (ε2 heterozygotes). In each individual allelic expression experiment, cDNA from heterozygotes was assayed as two separate RT reactions, alongside duplicates of the corresponding genomic DNA samples.
Each experiment was repeated on two separate occasions (i.e. a total of 3 experiments).
DNAse-treated RNA samples did not yield detectable product in the absence of an RT step. and loaded onto a 3100 DNA sequencer (Applied Biosystems). Products were electrophoresed on a 36cm capillary array at 60°C and data processed using Genescan Analysis version 3.7 software (Applied Biosystems). Peak heights of allele-specific extended primers were determined using Genotyper version 2.5 software (Applied Biosystems), and the ratios used as an index of the relative expression of the two alleles in each individual sample.
The same analytic conditions were used for genomic DNA and cDNA so that the average of all of the ratios observed in genomic DNA in each experiment (representing a 1:1 ratio of the two alleles) could be used to correct allelic ratios obtained from cDNA analyses for any inequalities in allelic representation specific to the assay (26) .
Statistical analysis
Differences in allelic expression were tested by comparing genomic ratios with cDNA ratios from the same heterozygous samples. All group comparisons were analyzed by t test (twotailed) or, where diagnosis was included as a factor, by two factorial ANOVA.
Predicted haplotype frequencies were calculated by use of EH plus (27) , and these formed the basis for calculation of individual diplotype probabilities. We calculate the probability that an individual carries a specific diplotype by first reconstructing all possible combinations of diplotypes for an individual given the observed genotypes at each locus. We then use the expected distribution of diplotype frequencies given the observed haplotypes frequencies within the specific sample to identify the most probable diplotype for that individual. The probability for the diplotype within an individual is then the frequency of that diplotype divided by the sum of the frequencies for all possible diplotypes.
Calculation of power to detect the effects of unknown regulatory variants is based upon the binomial distribution, Hardy-Weinberg equilibrium at the regulatory SNP, and no linkage disequilibrium (LD) with the marker SNP. The probability of an individual being homozygous at a putative regulatory locus with alleles in Hardy-Weinberg equilibrium is p 2 + q 2 , where p and q are the two allele frequencies. The probability that, of n individuals, all are homozygous (and therefore undetected by our assay) for the regulatory polymorphism is then
n . This also applies for n individuals selected for heterozygosity at the marker locus if there is no relationship (i.e. LD) between the genotypes at each locus. The power to detect at least one heterozygote is then 1-(p 2 + q
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Figure 1
Comparison between corrected genomic and cDNA ratios assayed at SNP 334T>C in ε3ε4 subjects. For all individuals, the C-allele determines ε4, and the T-allele determines ε3. The ratio is therefore expressed as the level of ε4 / ε3. Column 2 shows cDNA data points from non-AD cases (n = 15), and column 3 shows cDNA data points from confirmed LOAD cases (n = 11). The data for genomic DNA are the averages of 2 measurements for each individual sample. The data for cDNA are the averages of 6 estimates for each individual sample. For both non-AD and LOAD cases, the level of ε4 is significantly greater than ε3 in cDNA (P < 0.0001). No differences are observed in the extent of allelic distortion between non-AD and LOAD cases (P = 0.76).
Figure 2
Comparison between corrected genomic and cDNA ratios assayed at SNP 472C>T in (non-AD) ε2ε3 subjects (n = 11). For all individuals, the C-allele determines ε3 and the T-allele determines ε2. The ratio is therefore expressed as the level of ε3 / ε2. The data for genomic DNA are the averages of 2 measurements for each individual sample. The data for cDNA are the averages of 6 estimates for each individual sample. The level of the ε3 allele is slightly higher than ε2 in cDNA (P = 0.04).
Figure 3
Comparison between corrected ε4 / ε3 cDNA ratios from -219G>T homozygotes and -219G>T heterozygotes, as assayed at SNP 334T>C. Ratios derived from ε3ε4 heterozygotes that are also heterozygous for SNP -219G>T show lower ratios of ε4 / ε3 expression than do ε3ε4 heterozygotes that are homozygous for SNP -219G>T (P = 0.02).
Figure 4
Comparison between corrected ε4 / ε3 cDNA ratios from -491A>T homozygotes and -491A>T heterozygotes, as assayed at SNP 334T>C. No significant differences were observed between the two groups (P = 0.57). 
